Dapagliflozin in Depression

Summary

Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression

Eligibility

Inclusion Criteria:

Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Depressed patients for at least 2 months with Hamilton rating score more than 18.

Exclusion Criteria:

Patients with bipolar I or bipolar II disorder, personality disorders, and eating disorders.

Patients with substance dependence or abuse Patients with history of seizures or receiving electroconvulsive therapy (ECT) Patients with inflammatory disorders Patients with allergy or contraindications to the used medications Patients with finally pregnant or lactating females Diabetic patients Sever kidney disorders

Conditions1

Interventions2

Related trials

• Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS) — Xiangtan Central Hospital
• CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL — 4th Military Clinical Hospital with Polyclinic, Poland
• Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure — Fundación para la Investigación del Hospital Clínico de Valencia
• Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome — Future University in Egypt
• Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes — University of Sao Paulo
• SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes — The George Institute
• Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer — Washington University School of Medicine
• Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) — Washington University School of Medicine

Browse More Trials